Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
AZD7594 dose-ranging in mild to moderate asthma (14-day multiple dosing)
2014-005306-37Phase 2Completed
- Sponsor
- AstraZeneca
- Start
- Mar 2015
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial of velsecorat in asthma (4 arms), sponsored by AstraZeneca. Primary endpoint: Change in trough FEV1 from baseline. Started Mar 2015; status: completed.
02
Drugs
velsecorat
03
Conditions
asthma
Beyond the preview
Go deeper on 2014-005306-37.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2014-005306-37.